De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unrese

De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer is a phase 3, randomised interventional study registered as NCT06446557 by University Hospital, Rouen, with a registry enrolment figure of 408 participants, started 2026-06 and due to reach its primary completion in 2032-06-01. Interventions recorded: treatment adaptation guided by ctDNA variation; standard management. Conditions listed: Metastatic Colon Cancer. Primary outcome: Evaluate the superiority in quality-adjusted OS of an early treatment adaptation guided by ctDNA variation. Colorectal eligibility wording from the registry: "* Histologically proven diagnosis of RAS WT or mutant, MSS, BRAFV600E non-mutated colorectal cancer". Sites: France. No results are recorded here; the registry entry is the source.